eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study

Juan-Alfonso Soler (1) , Mercé Güell (2) , Meritxell Bricullé (3) , Antoni Gavarró (4) , Imma Roig (1) , Jordi Sanchez (5, 6) , Javier P. Gisbert (6, 7) , Pilar García (6, 5) , Albert Villoria (6, 5) , Xavier Calvet (6, 5)

1 Servei d'Hematologia, Hospital de Sabadell, Institut Universitari Parc Taulí
2 Servei de Cirurgia
3 Nefrology Department, Hospital de Sabadell, Institut Universitari Parc Taulí, Departament de Medicina
4 Laboratori d'Anàlisis Clinics UDIAT-CD Corporació Parc Taulí
5 Digestive Diseases Unit, Hospital de Sabadell, Institut Universitari Parc Taulí, Departament de Medicina
6 ISC - Instituto de Salud Carlos III [Madrid]
7 Hospital Universitario de La Princesa

Monoclonal gammopathy of unknown significance (MGUS) is a chronic haematological alteration that carries a 1% risk per year of malignant evolution. The origin of this disturbance remains unknown. Previous reports have suggested that a subgroup of patients presenting MGUS might cure after eradication. This study evaluates the effect of eradication in a cohort of 30 patients with MGUS. A 7-day clarithromycin-based triple treatment was prescribed to patients with MGUS infected with . Quantification of the monoclonal component was performed at inclusion and at least 12 months after treatment. The monoclonal component persisted unchanged in all patients who cured the infection.

Mots clés: Monoclonal gammopathy of unknown significance; Eradication therapy

Juan-Alfonso Soler, Mercé Güell, Meritxell Bricullé, Antoni Gavarró, Imma Roig, et al.. eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study. Annals of Hematology, 2009, 88 (8), pp.769-773. ⟨10.1007/s00277-008-0684-4⟩. ⟨hal-00535021⟩